
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Vemurafenib can treat melanoma and Erdheim Chester Disease.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:133
Suitable for treating adult patients with metastatic non-small cell lung cancer (NSCLC).【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:104
Alectinib treatment for non-small cell lung cancer.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:156
Overactive bladder (OAB)【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:38
Ibrutinib for the treatment of Chronic Lymphatic Leukemia【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:168
Afatinib can be used to treat Non Small Cell Lung Cancer.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:110
Tragliptin is suitable for type 2 diabetes.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:123
Fezolinetant is indicated for the treatment of vasomotor symptoms due to menopause.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:231
STIVARGA is indicated for the treatment of patients with metastatic colorectal cancer (CRC).【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:163
Tofacitinib is indicated for the treatment of adult patients with rheumatoid arthritis.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:164
Used in combination with other antihypertensive drugs for the treatment of hypertension.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:138
Used for treating advanced renal cell carcinoma following failure of a prior systemic therapy.【more】
Article source:Captain MedicineRelease date:2026-01-05Recommended:181
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended:[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended:[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended:[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended:[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended:[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended:[list:visits]2026-16-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643